Company Overview and News
VANCOUVER, British Columbia, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (MAX:TSX / MDRPF:OTCQX) today announced that the Nez Perce Tribal Executive Committee has adopted a resolution formally opposing the Company’s proposed Stibnite Gold Project. The Nez Perce Tribe is one of the three tribes being consulted by the U.S. Forest Service (“USFS”) under the National Environmental Policy Act review process.
VANCOUVER, B.C., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (MAX:TSX / MDRPF:OTCQX) today announced that the United States Forest Service (“USFS”) has provided its quarterly update to the anticipated permitting schedule for Midas Gold’s Stibnite Gold Project (“Project”), which is located in Valley County, 39 miles east of McCall and 14 miles from Yellow Pine, Idaho. The USFS, in cooperation with the six other federal, state and local agencies responsible for the permitting of the Project, anticipates issuing a draft Environmental Impact Statement (“EIS”) for public comment in May 2019, with a Final EIS and Draft Record of Decision (“ROD”) in February 2020.
Goldplat plc, the AIM listed gold producer, with international gold recovery operations located in South Africa and Ghana and a gold mine in Kenya is pleased to announce its preliminary results for the year ended 30 June 2018 (‘FY 2018’).
MALRY MDRPF MAX MALRF MIN PLG
VANCOUVER, British Columbia, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (MAX:TSX / MDRPF:OTCQX) (“Midas Gold” or the “Company”) today announced that Midas Gold Idaho, Inc., (“MGII” or “Midas Gold Idaho”) has appointed L. Michael Bogert as General Counsel of MGII, a wholly-owned subsidiary of Midas Gold Corp. and the operating company for the Stibnite Gold Project in central Idaho.
2018-07-28 seekingalpha - 1
Good day, ladies and gentlemen. Welcome to Vista Gold’s Second Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded. Today is Friday, July 27, 2018.
VGZ MDRPF MAX VGZ
2018-06-01 seekingalpha - 1
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my last update for April if you missed it.
ARCTF LUNMF NSRPF NEM YRI KGI.DB CG LUNCF MAX TMMFF NXXGD NSU CAGDF RSG AMI NXXGF AUY EDVVF RMGGF MDRPF IAG KL ABX EDV SAND SSL ABX SDDXF KGI NXS KGI.DB.A EDVMF NVO SNXZF ORG LUN TMR RMGGY EVR CANWF
VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX) (OTCQX:MDRPF) (“Midas Gold” or the “Company”) today announced that it has increased the size of its board of directors from seven to eight and appointed Mark Hill, Chief Investment Officer with Barrick Gold Corporation (NYSE:ABX) (TSX:ABX) (“Barrick”) to fill the additional position. The increase in board size and the appointment of a Barrick nominee to the board of directors is in accordance with the terms of the investor rights agreement entered into with Barrick in conjunction with the strategic investment by Barrick in Midas Gold that was completed on May 16, 2018.
ABX BLT BHPBF AU MAX AULGF BHP BBL MDRPF AGG BHP BHPLF ABX
Barrick Gold Corporation (ABX - Free Report) has purchased 46,551,731 common shares of Midas Gold Corp. for gross proceeds of roughly $38.1 million in a non-brokered private placement. As a result, Barrick Gold now owns 19.9% of issued and outstanding shares in Midas Gold. Barrick Gold’s latest move supports the continued efforts of Midas Gold to complete a feasibility study and permitting of the Stibnite Gold Project in Idaho.
HUN ABX WLK MDRPF MAX CC ABX
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX) (OTCQX:MDRPF) (“Midas Gold” or the “Company”) today announced that Barrick Gold Corporation (NYSE:ABX) (TSX:ABX) (“Barrick”) has purchased 46,551,731 common shares of Midas Gold in a non-brokered private placement (the “Placement”) at a price of C$1.06 per share for gross proceeds of US$38,065,907. As a result of the Placement, Barrick owns 19.
ABX MDRPF DTK MAX ABX
The West Texas Intermediate crude recently reached its highest point since November 2014, hitting $71.36 a barrel after President Trump’s announcement that the U.S. would pull out of the Iran nuclear deal.
RDS.B RDS.A XOM CVX RYDBF MDRPF MAX RDSB RDSA RYDAF
2018-05-10 zacks - 1
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 6 cents per share in the first quarter of 2018, in line with the Zacks Consensus Estimate and with the year-ago quarter.
ENTA CPRX LGNZZ LGND LGNYZ MDRPF CATB LGNXZ MAX LGNDZ
Gerdau S.A. reported impressive results for first-quarter 2018. The Brazilian steel maker’s adjusted net income totaled R$451.1 million ($138.8 million) in the reported quarter versus net loss of R$34.146 ($10.9 million) incurred in the year-ago quarter. The bottom line benefited from higher revenue generation, rise in adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) and fall in financial expenses.
MT STLD MDRPF MAX MT NUE
Inovio Pharmaceuticals, Inc. (INO - Free Report) reported a loss of 36 cents in the first quarter of 2018, wider than both the Zacks Consensus Estimate of a loss of 27 cents and the year-ago loss of 31 cents.
AZN INO AZN MDRPF MAX
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET